A Phase II Study of Docetaxel Before Medical Castration With Degarelix in Patients With Newly Diagnosed Metastatic Prostatic Adenocarcinoma
Latest Information Update: 26 Sep 2024
Price :
$35 *
At a glance
- Drugs Degarelix (Primary) ; Docetaxel (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 03 Sep 2024 Planned End Date changed from 30 Sep 2024 to 31 Dec 2024.
- 03 Sep 2024 Planned primary completion date changed from 31 Jul 2024 to 20 Sep 2024.
- 25 Jun 2024 Planned End Date changed from 31 Aug 2024 to 30 Sep 2024.